Related Experiment Video

Updated: May 14, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Oral renin inhibitors in clinical practice: a perspective review

Luca Bonanni1, Michele Dalla Vestra

  • 1Department of Internal Medicine, Ospedale dell'Angelo-General Hospital, Mestre-Venezia, Italy.

Therapeutic Advances in Chronic Disease
|January 24, 2013
PubMed

Insights

Aliskiren, a direct renin inhibitor, effectively lowers blood pressure and offers potential cardioprotective benefits. However, concerns regarding adverse effects led to the early termination of a major clinical trial.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Hypertension significantly increases cardiovascular morbidity and mortality.
  • The renin-angiotensin-aldosterone system (RAAS) plays a crucial role in cardiovascular and renal diseases.
  • Conventional therapies like ACE inhibitors and ARBs are mainstays of antihypertensive treatment.

Purpose of the Study:

  • To evaluate the efficacy and safety of aliskiren, a direct renin inhibitor (DRI).
  • To assess the potential cardioprotective and renoprotective effects of aliskiren.
  • To understand the role of DRIs in comprehensive RAAS inhibition.

Main Methods:

  • Clinical trials and in vitro studies were conducted.
  • Aliskiren's effects on blood pressure were compared to placebo and other antihypertensive agents.
  • Safety and adverse event profiles were monitored.

Main Results:

  • Aliskiren demonstrated superior reduction in systolic and diastolic blood pressure compared to placebo.
  • Aliskiren exhibited comparable efficacy to existing first-line antihypertensive agents.
  • Evidence suggests potential cardioprotective and renoprotective effects.

Conclusions:

  • Aliskiren is a well-tolerated oral direct renin inhibitor effective in lowering blood pressure.
  • Combination therapy with aliskiren may offer additional benefits.
  • Concerns regarding adverse effects, highlighted by the ALTITUDE study's early termination, warrant careful consideration.

Keywords:
aliskirendirect renin inhibitionhypertensionrenin–angiotensin–aldosterone system

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Renal Drug Clearance: Overview01:06

Renal Drug Clearance: Overview

Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Renal Drug Excretion: Overview01:15

Renal Drug Excretion: Overview

As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules out...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...